Lifecore Biomedical Q3 net loss widens to $40.08 million
Bitget2026/11/04 12:19- Lifecore Biomedical’s third-quarter 2026 net loss widened to $40.08 million from a year earlier.
- Revenues fell 19% year over year to $25.32 million.
- Two technology-transfer projects secured during the quarter are expected to contribute to long-term revenue growth beginning in 2027.
- Three development-phase programs secured early in the fourth quarter include one Phase 2 product and two Phase 3 products.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
